Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non‐small cell lung cancer patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-7714|6|5|620-628

ISSN： 1759-7706

Source： Thoracic Cancer, Vol.6, Iss.5, 2015-09, pp. : 620-628

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Platelet‐to‐lymphocyte ratio predicts the prognosis of patients with non‐small cell lung cancer treated with surgery and postoperative adjuvant chemotherapy

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 112-119

John Wiley & Sons Inc

Access to resources Recommend Favorite

Percutaneous radiofrequency ablation for medically inoperable patients with clinical stage I non‐small cell lung cancer

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 327-333

John Wiley & Sons Inc

Access to resources Recommend Favorite

Selection of proper candidates with resected pathological stage IIIA‐N2 non‐small cell lung cancer for postoperative radiotherapy

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 346-353

John Wiley & Sons Inc

Access to resources Recommend Favorite

Self‐reported depression among patients with non‐small cell lung cancer

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 334-337

John Wiley & Sons Inc

Access to resources Recommend Favorite

Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non‐small cell lung cancer

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 99-104

John Wiley & Sons Inc

Access to resources Recommend Favorite